Article info

Download PDFPDF

Original research
Long-term safety and effectiveness of canakinumab therapy in patients with cryopyrin-associated periodic syndrome: results from the β-Confident Registry

Authors

  1. Correspondence to Professor Ulrich A Walker; ulrich.walker{at}usb.ch
View Full Text

Citation

Walker UA, Tilson HH, Hawkins PN On behalf of the CACZ885D2401 Study Investigators, et al
Long-term safety and effectiveness of canakinumab therapy in patients with cryopyrin-associated periodic syndrome: results from the β-Confident Registry

Publication history

  • Received March 10, 2021
  • Revision received April 24, 2021
  • Accepted May 4, 2021
  • First published May 17, 2021.
Online issue publication 
May 17, 2021
  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.